PRECISION
MEDICINE
THE TIME
IS NOW
by Kathy Giusti, Executive Chairman and Founder
The Multiple Myeloma Research Foundation
Multiple myeloma, we now know, is not one disease; it’s many subtypes, each one driven by
mutated genes and other abnormalities that affect everything from how aggressive the disease
is to how likely a treatment is expected to work. Precisely selecting the best treatment based
on a person’s subtype rather than a one-size-fits-all-approach has the power to dramatically
transform the way we treat cancer. In some cancer, this approach — known as precision medicine
or personalized medicine — already has.
Lung cancer patients with tumo